Drs Ursula A. Matulonis and Leif W. Ellisen discuss endometrial cancer and ADCs, including resistance mechanisms, ADC sequencing, what's exciting in the field, and novel payloads.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001983. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

The Clinical Landscape of Antibody-Drug Conjugates in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/39074933/

FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

Mechanisms of Resistance to Antibody-Drug Conjugates https://pubmed.ncbi.nlm.nih.gov/36831621/

TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients With Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/39745368/

Single-Cell Analysis Technologies for Cancer Research: From Tumor-Specific Single Cell Discovery to Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/37900181/

Spatial Transcriptomics for Tumor Heterogeneity Analysis https://pubmed.ncbi.nlm.nih.gov/35899203/

Exploring Circulating Tumor DNA (CtDNA) and Its Role in Early Detection of Cancer: A Systematic Review https://pmc.ncbi.nlm.nih.gov/articles/PMC10516512/

Current and Emerging Prognostic Biomarkers in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35530346/

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/

Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients With Breast Cancer https://pubmed.ncbi.nlm.nih.gov/38709212/

Antibody-Drug Conjugates as Targeted Therapy for Treating Gynecologic Cancers: Update 2025 https://pubmed.ncbi.nlm.nih.gov/39480912/

Drs Ursula A. Matulonis and Joyce F. Liu discuss targeting DNA damage and repair and replication stress in endometrial cancer.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001982. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Exploiting Replicative Stress in Gynecological Cancers as a Therapeutic Strategy https://pubmed.ncbi.nlm.nih.gov/32571890/

Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling Into Place https://pubmed.ncbi.nlm.nih.gov/29653955/

WEE1 Inhibition in Cancer Therapy: Mechanisms, Synergies, Preclinical Insights, and Clinical Trials https://pubmed.ncbi.nlm.nih.gov/40187712/

Phase 2 Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma https://pubmed.ncbi.nlm.nih.gov/33705205/

ADAGIO: A Phase 2b, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.TPS5612

Azenosertib Monotherapy Yields Encouraging Responses in Cyclin E1+ Proc https://www.cancernetwork.com/view/azenosertib-monotherapy-yields-encouraging-responses-in-cyclin-e1-proc

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase 3 Duo-E Trial https://pubmed.ncbi.nlm.nih.gov/37864337/

Homologous Recombination Deficiency: Concepts, Definitions, and Assays https://pubmed.ncbi.nlm.nih.gov/35274707/

A Replication Stress Biomarker Is Associated With Response to Gemcitabine vs Combined Gemcitabine and ATR Inhibitor Therapy in Ovarian Cancer https://pubmed.ncbi.nlm.nih.gov/34552099/

Abstract B144: Discovery and Preclinical Evaluation of Novel Oral WEE1 Degraders https://aacrjournals.org/mct/article/22/12_Supplement/B144/730300/Abstract-B144-Discovery-and-preclinical-evaluation

Drs Ursula A. Matulonis and Gini Fleming discuss the state of endometrial cancer, the role of immunotherapy, and priorities for research in this field.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001981. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Cancer Statistics, 2025 https://pubmed.ncbi.nlm.nih.gov/39817679/

Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype https://pubmed.ncbi.nlm.nih.gov/35511145/

The Advent of Immune Checkpoint Inhibition for the Treatment of Patients With Primary Advanced or Recurrent dMMR/MSI High Endometrial Cancer in 2025 https://pubmed.ncbi.nlm.nih.gov/39611619/

Overall Survival in Patients With Endometrial Cancer Treated With Dostarlimab Plus Carboplatin-Paclitaxel in the Randomized ENGOT-EN6/GOG-3031/RUBY Trial https://pubmed.ncbi.nlm.nih.gov/38866180/

Safety and Antitumor Activity of Dostarlimab in Patients With Advanced or Recurrent DNA Mismatch Repair Deficient/Microsatellite Instability-High (dMMR/MSI-H) or Proficient/Stable (MMRp/MSS) Endometrial Cancer: Interim Results From GARNET-A Phase I, Single-Arm Study https://pubmed.ncbi.nlm.nih.gov/35064011/

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo) in Her2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma https://www.nrgoncology.org/Clinical-Trials/Protocol/nrg-gy026?filter=nrg-gy026

A New Vision for Women's Health Research: Transformative Change at the National Institutes of Health https://pubmed.ncbi.nlm.nih.gov/39652697/

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/

Antibody-Drug Conjugates as Targeted Therapy for Treating Gynecologic Cancers: Update 2025 https://pubmed.ncbi.nlm.nih.gov/39480912/

A Phase II Study of Frontline Paclitaxel/Carboplatin/Bevacizumab, Paclitaxel/Carboplatin/Temsirolimus, or Ixabepilone/Carboplatin/Bevacizumab in Advanced/Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/29804638/

Drs Ursula A. Matulonis and Katherine Fuh discuss the molecular classification and genetics of endometrial cancer as well as when to rebiopsy, research updates, and what's to come in the future.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001980. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists https://pubmed.ncbi.nlm.nih.gov/37627129/

Molecular Testing for Endometrial Cancer: An SGO Clinical Practice Statement https://pubmed.ncbi.nlm.nih.gov/36399812/

TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/36232987/

Histopathological Characterization of ProMisE Molecular Groups of Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/31932106/

Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02 https://pubmed.ncbi.nlm.nih.gov/39261417/

Randomized Phase III Trial of Radiation Therapy With or Without Pembrolizumab for Women With High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer (NRG-GY020) https://www.nrgoncology.org/Home/News/Post/randomized-phase-iii-trial-of-radiation-therapy-with-or-without-pembrolizumab-for-women-with-high-intermediate-risk-mismatch-repair-deficient-dmmr-endometrioid-endometrial-cancer-nrg-gy020

Testing Strategies for Lynch Syndrome in People With Endometrial Cancer https://www.medscape.co.uk/viewarticle/testing-strategies-lynch-syndrome-people-endometrial-cancer-2023a10001yb

Endometrial Cancer at Recurrence: To Re-sequence or Not to Re-sequence https://pubmed.ncbi.nlm.nih.gov/38841264/

Molecular Profiling of Primary Endometrioid Endometrial Cancer and Matched Lung Metastases: CTNNB1 Mutation as a Potential Driver https://pubmed.ncbi.nlm.nih.gov/38633674/

Route 66 Endometrial Cancer SPORE https://trp.cancer.gov/spores/abstracts/wustl_endometrial.htm

Project 2: Inhibiting AXL to Improve Treatment Response in Endometrial Cancer https://trp.cancer.gov/spores/abstracts/wustl_endometrial.htm#h04

AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA5515

Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer https://pubmed.ncbi.nlm.nih.gov/34884986/

GOG Foundation Overview https://www.gog.org/about/

Drs Ursula A. Matulonis and Eloise Chapman-Davis discuss overcoming health disparities in endometrial cancer and increasing clinical trial enrollment of Black women.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001979. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Cancer Statistics, 2025 https://pubmed.ncbi.nlm.nih.gov/39817679/

An Intervention-Based Approach to Achieve Racial Equity in Gynecologic Oncology https://pubmed.ncbi.nlm.nih.gov/37678907/

Patient Navigation in Cancer Treatment: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/38581470/

Disparities in the Allocation of Research Funding to Gynecologic Cancers by Funding to Lethality Scores https://pubmed.ncbi.nlm.nih.gov/30404721/

ECANA https://www.ecanawomen.org/

Racial Disparities in Diagnostic Evaluation of Uterine Cancer Among Medicaid Beneficiaries https://pubmed.ncbi.nlm.nih.gov/36788453/

Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35045221/

MedExplain https://medexplain.org/

PALS for Health https://www.palsforhealth.org/

Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss hormonal therapy updates and different ways to target and treat ER+ metastatic endometrial cancer.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001976. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Is the Positivity of Estrogen Receptor or Progesterone Receptor Different Between Type 1 and Type 2 Endometrial Cancer? https://pubmed.ncbi.nlm.nih.gov/27888807/

Immunophenotypic Diversity of Endometrial Adenocarcinomas: Implications for Differential Diagnosis https://pubmed.ncbi.nlm.nih.gov/16648864/

Progesterone: The Ultimate Endometrial Tumor Suppressor https://pubmed.ncbi.nlm.nih.gov/21353793/

Phase 2 Study of Anastrozole in Recurrent Estrogen (ER)/Progesterone (PR) Positive Endometrial Cancer: The PARAGON Trial - ANZGOG 0903 https://pubmed.ncbi.nlm.nih.gov/31130288/

Phase II Study of Fulvestrant in Recurrent/Metastatic Endometrial Carcinoma: A Gynecologic Oncology Group Study https://pubmed.ncbi.nlm.nih.gov/21075433/

Results From a Phase II Study to Assess the Efficacy and Tolerability of Fulvestrant 250 mg/Month as Treatment of Recurrent or Metastatic Endometrial Carcinoma https://ascopubs.org/doi/10.1200/jco.2009.27.15_suppl.5532

Phase II Trial of Alternating Courses of Megestrol Acetate and Tamoxifen in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study https://pubmed.ncbi.nlm.nih.gov/14751131/

Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/25624430/

A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy in Women With Advanced, Persistent or Recurrent Endometrial Carcinoma: A GOG Foundation Study https://pubmed.ncbi.nlm.nih.gov/35063278/

Everolimus, Letrozole, and Metformin in Women With Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study https://pubmed.ncbi.nlm.nih.gov/31628143/

A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36174113/

Elacestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial https://pubmed.ncbi.nlm.nih.gov/35584336/

CDKN2A Cyclin Dependent Kinase Inhibitor 2A [Homo sapiens (human)] https://www.ncbi.nlm.nih.gov/gene/1029

A Phase II Study of Fulvestrant Plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/39561275/

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, in Recurrent/Advanced ER-Positive Endometrioid Endometrial Cancer: Results From the Phase 1a/1b EMBER Study https://pubmed.ncbi.nlm.nih.gov/39442371

Palbociclib Plus Letrozole in Estrogen Receptor-Positive Advanced/Recurrent Endometrial Cancer: Double-Blind Placebo-Controlled Randomized Phase II ENGOT-EN3/PALEO Trial https://pubmed.ncbi.nlm.nih.gov/39657575/

Drs Ursula A. Matulonis and Akila N. Viswanathan discuss the role of radiation therapy in endometrial cancer, including staging, immunotherapy, and treatment disparities.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999853. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer Through Activation of Innate Immune Responses https://pubmed.ncbi.nlm.nih.gov/38169513/

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study https://pubmed.ncbi.nlm.nih.gov/16330675/

Adjuvant Chemotherapy Plus Radiation for Locally Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/31189035/

Adjuvant Chemoradiotherapy Versus Radiotherapy Alone for Women With High-Risk Endometrial Cancer (PORTEC-3): Final Results of an International, Open-Label, Multicentre, Randomised, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/29449189/

Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972022/

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972026/

FIGO Staging of Endometrial Cancer: 2023 https://pubmed.ncbi.nlm.nih.gov/37337978/

Polymerase ɛ (POLE) Mutations in Endometrial Cancer: Clinical Outcomes and Implications for Lynch Syndrome Testing https://pubmed.ncbi.nlm.nih.gov/25224212/

Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/37487144/

Risk Factors and Survival Impact Associated With Documentation of Radiation Therapy Refusal in Patients With Gynecologic Cancer https://pubmed.ncbi.nlm.nih.gov/37657506/

Drs Ursula A. Matulonis and Mansoor Mirza discuss immunotherapy trials, novel therapies such as CDK4/6 inhibitors and antibody-drug conjugates, and shared decision-making.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999852. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972026/

Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972022/

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial https://pubmed.ncbi.nlm.nih.gov/37864337/

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209) https://pubmed.ncbi.nlm.nih.gov/33078978/

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/37669480/

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/

Drs Ursula A. Matulonis and Bhavana Pothuri discuss solutions to address health disparities in the diagnosis and treatment of endometrial cancer.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999851. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Differential Trends in Rising Endometrial Cancer Incidence by Age, Race, and Ethnicity https://pubmed.ncbi.nlm.nih.gov/36625534/

Risk of Female-Specific Cancers According to Obesity and Menopausal Status in 2.7 Million Korean Women: Similar Trends Between Korean and Western Women https://pubmed.ncbi.nlm.nih.gov/34327357/

Uterine Cancer Is on the Rise, Especially Among Black Women https://www.nytimes.com/2022/06/17/health/uterine-cancer-black-women.html

New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines https://pubmed.ncbi.nlm.nih.gov/34073635/

A Molecular Perspective: Racial Disparities in Uterine Serous Carcinoma https://www.sciencedirect.com/science/article/abs/pii/S0090825822013105

Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives for Therapy https://pubmed.ncbi.nlm.nih.gov/38529411/

Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/30741844/

Demographic Reporting and Language Exclusion in Gynecologic Oncology Clinical Trials https://pubmed.ncbi.nlm.nih.gov/37751830/

What's in It for Me?: A Value Assessment of Gynecologic Cancer Clinical Trials for Black Women https://pubmed.ncbi.nlm.nih.gov/36931101/

Just Ask! Increasing Diversity in Cancer Clinical Research https://courses.accc-cancer.org/products/just-ask-increasing-diversity-in-cancer-clinical-research#tab-product_tab_overview

Translational Research: Bridging the Gap Between Preclinical and Clinical Research https://pubmed.ncbi.nlm.nih.gov/36722550/

WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer Through Activation of Innate Immune Responses https://pubmed.ncbi.nlm.nih.gov/38169513/

ROCC/GOG-3043: A Randomized Non-inferiority Trial of Robotic Versus Open Radical Hysterectomy for Early-Stage Cervical Cancer https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS5605

Diverse Trials Act https://aaci-library.org/legislation-tracker/diverse-trials-act

Drs Ursula A. Matulonis and Joyce F. Liu discuss new therapeutics for patients with endometrial cancer, including ADCs, immunotherapy, and drugs targeting replication stress.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999850. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Advances in Chemotherapy and Targeted Therapies in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36291804/

Uterine Cancer https://emedicine.medscape.com/article/258148-overview

Integrated Genomic Characterization of Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/23636398/

Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability https://pubmed.ncbi.nlm.nih.gov/33182707/

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972026/

Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972022/

PDUFA VII: Fiscal Years 2023-2027 https://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-vii-fiscal-years-2023-2027

NCCN Drugs & Biologics Compendium https://www.nccn.org/docs/default-source/clinical/drugs-and-biologics-compendium-user-guide.pdf

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma https://pubmed.ncbi.nlm.nih.gov/37627113/

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu https://pubmed.ncbi.nlm.nih.gov/29584549/

Uterine Serous Carcinoma https://pubmed.ncbi.nlm.nih.gov/33934848/

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma https://clinicaltrials.gov/study/NCT05256225

HER2 Amplification in p53-Mutated Endometrial Carcinomas https://pubmed.ncbi.nlm.nih.gov/36900227/

Researches on the Correlation Between Estrogen and Progesterone Receptors Expression and Disease-Free Survival of Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/33335423/

Application of NGS Molecular Classification in the Diagnosis of Endometrial Carcinoma: A Supplement to Traditional Pathological Diagnosis https://pubmed.ncbi.nlm.nih.gov/36341543/

FIGO Staging of Endometrial Cancer: 2023 https://pubmed.ncbi.nlm.nih.gov/37337978/

The Role of Immunotherapy in Advanced and Recurrent MMR Deficient and Proficient Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/36493574/

Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35045221/

Phase 3, Randomized, Open-Label Study of Pembrolizumab Plus Lenvatinib Versus Chemotherapy for First-Line Treatment of Advanced or Recurrent Endometrial Cancer: ENGOT-en9/LEAP-001 https://pubmed.ncbi.nlm.nih.gov/34799418/

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology https://pubmed.ncbi.nlm.nih.gov/27841667/

FDA Grants Accelerated Approval to Fam-trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2